Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-infected Patients During Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2002 Oct 2

PMID 12354872

Citations 33

Authors

Anna S F Lok

Fabien Zoulim

Stephen Locarnini

Alessandra Mangia

Grazia Niro

Hilde Decraemer

Geert Maertens

Frank Hulstaert

Karen De Vreese

Erwin Sablon

Affiliations

Soon will be listed here.

Abstract

Sensitive and early detection of emerging hepatitis B virus (HBV) drug resistance may not only help monitor the viral dynamics associated with lamivudine treatment but could also improve therapeutic decision making. This is especially important when new antivirals effective against lamivudine-resistant HBV become available. A total of 159 serum samples from 33 chronic HBV patients receiving lamivudine treatment were analyzed at four centers for the presence of lamivudine-resistant mutations at codons 528 [180] (proposed revised nomenclature according to Stuyver et al. [Hepatology 33:751-757, 2001] shown in brackets), 552 [204], and 555 [207] of the HBV polymerase. Sequencing data were compared with results generated by the INNO-LiPA HBV DR line probe assay (LiPA), an assay based on reverse hybridization of amplified HBV DNA fragments with specific nucleotide probes immobilized on nitrocellulose strips. LiPA provided at least the same information as sequencing for 97.5% of all codons analyzed for codon 528 [180], 95% for codon 552 [204], and 100% for codon 555 [207]. The most common reason for discrepant or indeterminate results (0.4% and 1.5%, respectively) in a small percentage of the population tested could be attributed to polymorphisms not yet covered by LiPA probes. In at least five patients, a mutant could be detected earlier by LiPA than by sequencing. In 15 patients, LiPA detected mixed wild-type and mutant virus populations before viral breakthrough. These results demonstrate that INNO-LiPA HBV DR is a highly sensitive and easily applicable assay for the detection and monitoring of lamivudine-resistant mutations in chronic hepatitis B patients and that the assay is more sensitive than sequencing in detecting mixed mutant and wild-type sequences.

Citing Articles

Evaluating the Efficacy of Repurposed Antiretrovirals in Hepatitis B Virus Treatment: A Narrative Review of the Pros and Cons.

Ugbaja S, Omerigwe S, Ndlovu S, Ngcobo M, Gqaleni N Int J Mol Sci. 2025; 26(3).

PMID: 39940695 PMC: 11817041. DOI: 10.3390/ijms26030925.

A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals.

Nicolini L, Orsi A, Tatarelli P, Viscoli C, Icardi G, Sticchi L Int J Environ Res Public Health. 2019; 16(18).

PMID: 31505743 PMC: 6766235. DOI: 10.3390/ijerph16183307.

Detection of Hepatitis B Virus M204I Mutation by Quantum Dot-Labeled DNA Probe.

Zhang C, Chen Y, Liang X, Zhang G, Ma H, Nie L Sensors (Basel). 2017; 17(5).

PMID: 28445403 PMC: 5461085. DOI: 10.3390/s17050961.

Evaluation of antiviral resistant hepatitis B virus subpopulations in patients with chronic hepatitis B by using terminal restriction fragment length polymorphism.

Sahin E Virusdisease. 2015; 26(4):267-75.

PMID: 26645037 PMC: 4663704. DOI: 10.1007/s13337-015-0282-8.

Application of coamplification at lower denaturation temperature-PCR sequencing for early detection of antiviral drug resistance mutations of hepatitis B virus.

Wong D, Tsoi O, Huang F, Seto W, Fung J, Lai C J Clin Microbiol. 2014; 52(9):3209-15.

PMID: 24951803 PMC: 4313139. DOI: 10.1128/JCM.00343-14.

References

Gunther S, von Breunig F, Santantonio T, Jung M, Gaeta G, Fischer L . Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. J Hepatol. 1999; 30(5):749-54. DOI: 10.1016/s0168-8278(99)80124-x. View

Pichoud C, Seigneres B, Wang Z, Trepo C, Zoulim F . Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology. 1998; 29(1):230-7. DOI: 10.1002/hep.510290119. View

Hussain M, Lok A . Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J Viral Hepat. 1999; 6(3):183-94. DOI: 10.1046/j.1365-2893.1999.00160.x. View

Stuyver L, Van Geyt C, Gendt S, van Reybroeck G, Zoulim F, Leroux-Roels G . Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol. 2000; 38(2):702-7. PMC: 86181. DOI: 10.1128/JCM.38.2.702-707.2000. View

Hunt C, McGill J, Allen M, Condreay L . Clinical relevance of hepatitis B viral mutations. Hepatology. 2000; 31(5):1037-44. DOI: 10.1053/he.2000.6709. View

Yeh C, Chien R, Chu C, Liaw Y . Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology. 2000; 31(6):1318-26. DOI: 10.1053/jhep.2000.7296. View

Van Laethem K, Van Vaerenbergh K, Schmit J, Sprecher S, Hermans P, De Vroey V . Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr. 2000; 22(2):107-18. DOI: 10.1097/00126334-199910010-00001. View

Leung N . Nucleoside analogues in the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2000; 15 Suppl:E53-60. DOI: 10.1046/j.1440-1746.2000.02103.x. View

Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L . Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology. 2000; 32(5):1078-88. DOI: 10.1053/jhep.2000.19619. View

10.

Farrell G . Clinical potential of emerging new agents in hepatitis B. Drugs. 2000; 60(4):701-10. DOI: 10.2165/00003495-200060040-00001. View

11.

Maddrey W . Hepatitis B--an important public health issue. Clin Lab. 2001; 47(1-2):51-5. View

12.

Lin O, Keeffe E . Current treatment strategies for chronic hepatitis B and C. Annu Rev Med. 2001; 52:29-49. DOI: 10.1146/annurev.med.52.1.29. View

13.

Stuyver L, Locarnini S, Lok A, Richman D, Carman W, Dienstag J . Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology. 2001; 33(3):751-7. DOI: 10.1053/jhep.2001.22166. View

14.

Aberle S, Kletzmayr J, Watschinger B, Schmied B, Vetter N, Puchhammer-Stockl E . Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol. 2001; 39(5):1972-4. PMC: 88061. DOI: 10.1128/JCM.39.5.1972-1974.2001. View

15.

Richman D . Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antivir Ther. 2001; 6(2):83-8. View

16.

de Man R, Wolters L, Nevens F, Chua D, Sherman M, Lai C . Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology. 2001; 34(3):578-82. DOI: 10.1053/jhep.2001.26815. View

17.

Benhamou Y, BOCHET M, Thibault V, Calvez V, Fievet M, Vig P . Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet. 2001; 358(9283):718-23. DOI: 10.1016/s0140-6736(01)05840-8. View

18.

Rousseau F, Kahn J, Thompson M, Mildvan D, Shepp D, Sommadossi J . Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother. 2001; 48(4):507-13. DOI: 10.1093/jac/48.4.507. View

19.

Yuen M, Sablon E, Hui C, Yuan H, Decraemer H, Lai C . Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001; 34(4 Pt 1):785-91. DOI: 10.1053/jhep.2001.27563. View

20.

Pas S, de Man R, Fries E, Osterhaus A, Niesters H . The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation. J Clin Virol. 2002; 25(1):63-71. DOI: 10.1016/s1386-6532(01)00251-7. View